[go: up one dir, main page]

PL3806884T3 - Ogólny motyw oddziaływania z amyloidem (gaim) - Google Patents

Ogólny motyw oddziaływania z amyloidem (gaim)

Info

Publication number
PL3806884T3
PL3806884T3 PL19739769.8T PL19739769T PL3806884T3 PL 3806884 T3 PL3806884 T3 PL 3806884T3 PL 19739769 T PL19739769 T PL 19739769T PL 3806884 T3 PL3806884 T3 PL 3806884T3
Authority
PL
Poland
Prior art keywords
gaim
interaction motif
amyloid interaction
general
general amyloid
Prior art date
Application number
PL19739769.8T
Other languages
English (en)
Inventor
Rajaraman Krishnan
Eva ASP
Ming PROSCHITSKY
Richard Fisher
Original Assignee
Amyl Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amyl Therapeutics filed Critical Amyl Therapeutics
Publication of PL3806884T3 publication Critical patent/PL3806884T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/14011Details ssDNA Bacteriophages
    • C12N2795/14111Inoviridae
    • C12N2795/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/14011Details ssDNA Bacteriophages
    • C12N2795/14111Inoviridae
    • C12N2795/14133Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL19739769.8T 2018-06-15 2019-06-14 Ogólny motyw oddziaływania z amyloidem (gaim) PL3806884T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685757P 2018-06-15 2018-06-15
US201862749499P 2018-10-23 2018-10-23
PCT/US2019/037179 WO2019241628A1 (en) 2018-06-15 2019-06-14 General amyloid interaction motif (gaim)

Publications (1)

Publication Number Publication Date
PL3806884T3 true PL3806884T3 (pl) 2023-11-20

Family

ID=67263052

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19739769.8T PL3806884T3 (pl) 2018-06-15 2019-06-14 Ogólny motyw oddziaływania z amyloidem (gaim)

Country Status (14)

Country Link
US (2) US11692017B2 (pl)
EP (2) EP3806884B1 (pl)
JP (1) JP7549536B2 (pl)
CN (1) CN112672755A (pl)
AU (1) AU2019287623B2 (pl)
BR (1) BR112020025111A2 (pl)
CA (1) CA3102841A1 (pl)
ES (1) ES2960493T3 (pl)
IL (1) IL279333B2 (pl)
MX (1) MX2020013525A (pl)
PL (1) PL3806884T3 (pl)
SG (1) SG11202012091WA (pl)
WO (1) WO2019241628A1 (pl)
ZA (1) ZA202100071B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020025111A2 (pt) * 2018-06-15 2021-04-06 Proclara Biosciences, Inc. Motivo de interação amiloide geral (gaim)
EP3927725A4 (en) * 2019-02-22 2023-06-14 Loyola Marymount University AMYLOID PEPTIDE VARIANTS
WO2024119183A1 (en) 2022-12-02 2024-06-06 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate
CN117343200B (zh) * 2023-12-04 2024-01-30 北京质肽生物医药科技有限公司 一种包含淀粉样核心多肽的融合蛋白、制备方法及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ, インコーポレイテッド IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変
CN114748605A (zh) 2011-11-29 2022-07-15 普罗克拉拉生物科学股份有限公司 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
MX358755B (es) 2012-10-02 2018-09-03 Proclara Biosciences Inc Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides.
EP3003349B1 (en) 2013-05-28 2018-12-12 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
WO2016090022A1 (en) * 2014-12-03 2016-06-09 Neurophage Pharmaceuticals, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal
BR112020025111A2 (pt) * 2018-06-15 2021-04-06 Proclara Biosciences, Inc. Motivo de interação amiloide geral (gaim)

Also Published As

Publication number Publication date
AU2019287623A1 (en) 2021-01-07
SG11202012091WA (en) 2021-01-28
CN112672755A (zh) 2021-04-16
AU2019287623B2 (en) 2024-11-07
MX2020013525A (es) 2021-02-26
ES2960493T3 (es) 2024-03-05
EP3806884B1 (en) 2023-08-02
EP4389154A3 (en) 2024-11-13
ZA202100071B (en) 2023-04-26
JP7549536B2 (ja) 2024-09-11
BR112020025111A2 (pt) 2021-04-06
EP3806884A1 (en) 2021-04-21
EP4389154A2 (en) 2024-06-26
US20210246179A1 (en) 2021-08-12
US12247055B2 (en) 2025-03-11
US20230279064A1 (en) 2023-09-07
US11692017B2 (en) 2023-07-04
IL279333B2 (en) 2023-06-01
IL279333A (en) 2021-01-31
WO2019241628A1 (en) 2019-12-19
EP3806884C0 (en) 2023-08-02
JP2021527407A (ja) 2021-10-14
CA3102841A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
ZA202100071B (en) General amyloid interaction motif (gaim)
GB201800761D0 (en) Interaction between blockchains
ZA202103963B (en) Hot-extraction paper
SG11202101033YA (en) Benzene derivative
EP3784831C0 (de) Stoffauflöser
GB201805799D0 (en) b
GB2576943B (en) Flushing machine
PL3805545T3 (pl) Cylindryczny element
GB201906000D0 (en) Structural element
GB201900558D0 (en) Concept A2
GB201814379D0 (en) Concept four
GB201900555D0 (en) Concept one
GB201901706D0 (en) b
GB201811625D0 (en) Concept One
HU4942U (hu) Elektrohidraulikus sorompó mûködtetõ szerkezet
GB201814414D0 (en) Concept 36a
GB201811476D0 (en) Hotel
GB201807085D0 (en) Concept 36a
GB201807117D0 (en) Concept 32
GB201807108D0 (en) Concept 156
GB201807104D0 (en) Concept 30
GB201807079D0 (en) Concept 168
GB201807078D0 (en) Concept 169
GB201807127D0 (en) Concept 39
GB201807126D0 (en) Concept 364